DB:5IV1

Stock Analysis Report

Executive Summary

IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer.


Snowflake Analysis

Slightly overvalued with limited growth.


Similar Companies

Share Price & News

How has IMV's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 5IV1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.5%

5IV1

-1.8%

DE Biotechs

0.1%

DE Market


1 Year Return

-6.6%

5IV1

7.2%

DE Biotechs

14.1%

DE Market

Return vs Industry: 5IV1 underperformed the German Biotechs industry which returned 7.2% over the past year.

Return vs Market: 5IV1 underperformed the German Market which returned 14.1% over the past year.


Shareholder returns

5IV1IndustryMarket
7 Day1.5%-1.8%0.1%
30 Day14.5%-2.9%0.2%
90 Day92.2%5.8%3.3%
1 Year-6.6%-6.6%7.5%7.2%17.6%14.1%
3 Year27.7%27.7%42.8%41.2%14.8%4.8%
5 Year157.3%157.3%11.6%9.3%22.2%5.4%

Price Volatility Vs. Market

How volatile is IMV's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is IMV undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 5IV1 (€3.78) is trading below our estimate of fair value (€11.95)

Significantly Below Fair Value: 5IV1 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 5IV1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 5IV1 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 5IV1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 5IV1 is overvalued based on its PB Ratio (20.1x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is IMV forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

29.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 5IV1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 5IV1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 5IV1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 5IV1's revenue (63.2% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 5IV1's revenue (63.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 5IV1's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has IMV performed over the past 5 years?

-31.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 5IV1 is currently unprofitable.

Growing Profit Margin: 5IV1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 5IV1 is unprofitable, and losses have increased over the past 5 years at a rate of -31.2% per year.

Accelerating Growth: Unable to compare 5IV1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5IV1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 5IV1 has a negative Return on Equity (-181.45%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is IMV's financial position?


Financial Position Analysis

Short Term Liabilities: 5IV1's short term assets (CA$27.4M) exceed its short term liabilities (CA$6.1M).

Long Term Liabilities: 5IV1's short term assets (CA$27.4M) exceed its long term liabilities (CA$9.6M).


Debt to Equity History and Analysis

Debt Level: 5IV1's debt to equity ratio (57.5%) is considered high.

Reducing Debt: 5IV1's debt to equity ratio has increased from 31.9% to 57.5% over the past 5 years.


Balance Sheet

Inventory Level: 5IV1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 5IV1's debt is covered by short term assets (assets are 3.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 5IV1 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 5IV1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -31.2% each year


Next Steps

Dividend

What is IMV's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 5IV1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 5IV1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 5IV1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 5IV1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 5IV1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Fred Ors (45yo)

3.8yrs

Tenure

CA$1,335,893

Compensation

Mr. Frederic Ors, also known as Fred, B.Sc., M.A., has been Chief Executive Officer of IMV Inc. since April 14, 2016 and served as its President. Mr. Ors served as Acting Chief Executive Officer of IMV Inc ...


CEO Compensation Analysis

Compensation vs Market: Fred's total compensation ($USD1.01M) is above average for companies of similar size in the German market ($USD620.49K).

Compensation vs Earnings: Fred's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Frederic Ors
CEO & Director3.8yrsCA$1.34m0.31% CA$635.1k
Pierre Labbé
Chief Financial Officer3yrsCA$882.87k0.28% CA$571.1k
Joseph Sullivan
Senior Vice President of Business Development2.1yrsCA$743.94k0.0089% CA$18.3k
Marc Jasmin
Senior Director of Investor Relations & Communications1.2yrsno datano data
Joanne Schindler
Chief Medical Officer0.3yrsno datano data

2.1yrs

Average Tenure

Experienced Management: 5IV1's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Frederic Ors
CEO & Director3.8yrsCA$1.34m0.31% CA$635.1k
James Hall
Independent Director10yrsCA$112.60k0.15% CA$314.7k
Shermaine Tilley
Independent Director3.7yrsno datano data
Julia Gregory
Independent Director1.7yrsCA$161.70kno data
Andrew Sheldon
Independent Chairman of the Board3.8yrsCA$179.00k0.20% CA$412.2k
Wayne Pisano
Independent Director8.3yrsCA$118.00k0.15% CA$314.0k
Albert Scardino
Independent Director9.6yrsCA$104.00k4.67% CA$9.6m
Adekunle Odunsi
Member of Scientific & Clinical Advisory Committee0yrsno datano data
David Spaner
Member of Scientific & Clinical Advisory Committee0yrsno datano data
Brad Nelson
Member of Scientific & Clinical Advisory Committee0yrsno datano data

3.8yrs

Average Tenure

67yo

Average Age

Experienced Board: 5IV1's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.5%.


Top Shareholders

Company Information

IMV Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IMV Inc.
  • Ticker: 5IV1
  • Exchange: DB
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$293.659m
  • Listing Market Cap: CA$205.682m
  • Shares outstanding: 50.63m
  • Website: https://imv-inc.com

Number of Employees


Location

  • IMV Inc.
  • 130 Eileen Stubbs Avenue
  • Suite 19
  • Dartmouth
  • Nova Scotia
  • B3B 2C4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMVTSX (The Toronto Stock Exchange)YesCommon SharesCACADOct 2009
IMVNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDOct 2009
5IV1DB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2009

Biography

IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company’s DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. IMV Inc. has collaboration and license agreements with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis and The Wistar Institute; and a preclinical therapeutic research collaboration with Navidea Biopharmaceuticals, Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 22:40
End of Day Share Price2020/02/19 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.